The in vitro activity of gemifloxacin was compared to that of other quinolone and nonquinolone antimicrobials against 204 anaerobes by the agar dilution technique. The data indicate that gemifloxacin has a rather selective anaerobic activity. Most Peptostreptococcus, Porphyromonas, and Fusobacterium species are susceptible, while gemifloxacin's activity against other gram-negative anaerobes appears to be variable.
were prepared for all compounds tested. Dilutions of the antibiotics were made according to standard procedures on the day of the test. Inocula were prepared according to NCCLS standards (13) . The final inoculum density was calculated to be approximately 10 5 CFU/spot. The individual inocula were applied by use of a semiautomatic replicator device (A400 Multipoint Inoculator; Bachhofer GmbH, Reutlingen, Germany). The MICs were determined after incubation in an anaerobic chamber (WA 6600; Heraeus Instruments, Hanau, Germany) containing an atmosphere of 80% N 2 , 15% CO 2 , and 5% H 2 for 48 h at 37°C. Bacteroides fragilis ATCC 25285 and Bacteroides thetaiotaomicron ATCC 29741 served as controls to monitor the stability of the antimicrobial preparations. Antimicrobial reference powders were as follows: gemifloxacin and amoxicillin-clavulanate (2:1) (SmithKline Beecham Pharma GmbH, Munich, Germany); moxifloxacin (Bayer, Leverkusen, Germany); penicillin G (Serva, Heidelberg, Germany); imipenem (MSD, Haar, Germany); and clindamycin and metronidazole (Sigma, Steinheim, Germany).
The MIC 90 s of gemifloxacin were equal to or one to two dilutions lower than those of moxifloxacin against various species of Peptostreptococcus. The MIC 90 s for Peptostreptococcus asacharolyticus, P. micros, and P. prevotii were between 0.125 and 0.25 mg/liter. However, some isolates of P. anaerobius and P. magnus were resistant, resulting in gemifloxacin MIC 90 s of 0.5 and 4 mg/liter, respectively, indicating that the activity of gemifloxacin is not entirely predictable, even against grampositive anaerobes, and that there is species variability in its activity against peptostreptoccoci. Goldstein et al. (8) noted far lower MIC 90 s for these species (0.03 and 0.06 mg/liter, respectively). Interestingly, the MIC ranges at least of P. anaerobius indicate that Goldstein similarly found isolates for which the MICs were up to 8 mg/liter, so that the differences may be explained by the significantly smaller number of isolates tested in Goldstein's study (13 versus Most of the isolates tested in our study were Prevotella melaninogenica and P. intermedia, corresponding to the more resistant species of the isolates tested by Goldstein et al. Therefore, discrepancies between the studies in the overall activity of gemifloxacin against Prevotella may be explained by the marked differences in susceptibility of the various species.
All Porphyromonas isolates tested, including strains of Porphyromonas gingivalis (13) , P. endodontalis (3), P. asaccharolytica (2), and P. levii (2), were inhibited by Յ0.125 mg of gemifloxacin per liter.
Most of the fusobacteria in our study were also susceptible to gemifloxacin, with an MIC 90 of 0.5 mg/liter. The activity of gemifloxacin against fusobacteria was one to two dilutions lower than that of moxifloxacin. The majority of strains included in our study were Fusobacterium necrophorum (16 of 24) and F. nucleatum (6 of 24). Goldstein et al. (9) reported similar MIC 90 values for these species (0.5 and 0.25 mg/liter, respectively).
All anaerobes tested in this study were susceptible to the comparator antimicrobials imipenem and amoxicillin-clavulanate according to NCCLS criteria (13) . For metronidazole and clindamycin, the overall susceptibility rates were 98 and 93%, respectively. As judged by the difference between penicillin and amoxicillin-clavulanate susceptibility, 26% of the isolates were lactamase producers.
In conclusion, the antimicrobial potency of gemifloxacin against anaerobic bacteria appears to be variable. In accordance with previously published studies, the majority of the Peptostreptococcus and Porphyromonas strains appear to be susceptible. Yet the present study shows that unequal susceptibilities between species of the same genus exist. Furthermore, possible variations between local susceptibility patterns must be taken into account when the use of gemifloxacin in treating anaerobic infections by these species is considered. Compared to the general resistance of fusobacteria toward the older quinolones (6), gemifloxacin clearly shows enhanced activity against these pathogens. Against other gram-negative anaerobes gemifloxacin exhibits only moderate activity. Considered in light of the complex nature of most anaerobic infections, the data presented here must be regarded as preliminary, and further clinical studies appear warranted to evaluate the role of gemifloxacin in such infections. (2) , and P. levii (2) . c That is, Prevotella melaninogenica (10), P. oris (4), P. intermedia (3), P. bivia (1), P. buccae (1), P. denticola (1), and P. disiens (1) .
